MX2019011117A - Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. - Google Patents

Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.

Info

Publication number
MX2019011117A
MX2019011117A MX2019011117A MX2019011117A MX2019011117A MX 2019011117 A MX2019011117 A MX 2019011117A MX 2019011117 A MX2019011117 A MX 2019011117A MX 2019011117 A MX2019011117 A MX 2019011117A MX 2019011117 A MX2019011117 A MX 2019011117A
Authority
MX
Mexico
Prior art keywords
antigen
antibody
binding fragment
medical use
medicament
Prior art date
Application number
MX2019011117A
Other languages
English (en)
Inventor
Zhang Ting
Ye Xin
Tao Weikang
Zhang Lianshan
Gu Jinming
Wang Xiaohua
Yang Liuqing
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2019011117A publication Critical patent/MX2019011117A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Abstract

La invención proporciona un anticuerpo B7-H3, un fragmento de unión a antígeno del mismo y un uso médico del mismo. Además, la presente invención describe una composición farmacéutica que comprende el anticuerpo B7-H3 o fragmento de unión a antígeno del mismo, y el uso del mismo como medicamento. En particular, la invención describe un uso de un anticuerpo B7-H3 humano o un fragmento de unión a antígeno del mismo para 10 la fabricación de un medicamento para el tratamiento de una enfermedad o afección asociada a B7-H3.
MX2019011117A 2017-03-31 2018-03-30 Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. MX2019011117A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710206261 2017-03-31
PCT/CN2018/081249 WO2018177393A1 (zh) 2017-03-31 2018-03-30 B7-h3抗体、其抗原结合片段及其医药用途

Publications (1)

Publication Number Publication Date
MX2019011117A true MX2019011117A (es) 2019-11-05

Family

ID=63674249

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011117A MX2019011117A (es) 2017-03-31 2018-03-30 Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.

Country Status (13)

Country Link
US (2) US10899837B2 (es)
EP (1) EP3604337A4 (es)
JP (1) JP7158403B2 (es)
KR (1) KR20190134614A (es)
CN (1) CN109937212B (es)
AU (1) AU2018243123A1 (es)
BR (1) BR112019019111A2 (es)
CA (1) CA3056474A1 (es)
MX (1) MX2019011117A (es)
RU (1) RU2765306C2 (es)
TW (1) TWI796328B (es)
UA (1) UA125593C2 (es)
WO (1) WO2018177393A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018243123A1 (en) 2017-03-31 2019-09-26 Changzhou Hansoh Pharmaceutical Co., Ltd. B7-H3 antibody, antigen-binding fragment thereof and medical use thereof
TW201909926A (zh) * 2017-08-04 2019-03-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｂ７ｈ３抗體－藥物偶聯物及其醫藥用途
US11403813B2 (en) 2019-11-26 2022-08-02 Sdc U.S. Smilepay Spv Systems and methods for constructing a three-dimensional model from two-dimensional images
US10916053B1 (en) 2019-11-26 2021-02-09 Sdc U.S. Smilepay Spv Systems and methods for constructing a three-dimensional model from two-dimensional images
US11270523B2 (en) 2017-11-29 2022-03-08 Sdc U.S. Smilepay Spv Systems and methods for constructing a three-dimensional model from two-dimensional images
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
WO2020114479A1 (zh) * 2018-12-07 2020-06-11 江苏恒瑞医药股份有限公司 多特异性蛋白分子
US11030801B2 (en) 2019-05-17 2021-06-08 Standard Cyborg, Inc. Three-dimensional modeling toolkit
KR20210006637A (ko) * 2019-07-09 2021-01-19 주식회사 와이바이오로직스 B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
US20220332829A1 (en) * 2019-09-16 2022-10-20 Nanjing Sanhome Pharmaceutical Co., Ltd. Anti-b7-h3 antibody and application thereof
WO2021260438A1 (en) * 2020-06-26 2021-12-30 Intocell, Inc. Antibody-drug conjugates comprising anti-b7-h3 antibodies
CN115279417A (zh) * 2021-02-09 2022-11-01 苏州宜联生物医药有限公司 生物活性物偶联物及其制备方法和用途
WO2022203414A1 (ko) * 2021-03-26 2022-09-29 세라노틱스(주) B7-h3 항체 또는 이의 항원 결합 단편 및 이의 용도
WO2023160376A1 (en) * 2022-02-25 2023-08-31 Nanjing Probio Biotech Co., Ltd. Antibodies and variants thereof against human b7-h3
TW202402808A (zh) * 2022-05-18 2024-01-16 中國大陸商上海藥明生物技術有限公司 抗-b7h3抗體及其用途
WO2023221975A1 (zh) * 2022-05-18 2023-11-23 苏州宜联生物医药有限公司 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US20050002935A1 (en) * 2003-04-17 2005-01-06 Vincent Ling Use of B7-H3 as an immunoregulatory agent
CN101104639A (zh) 2006-07-10 2008-01-16 苏州大学 抗人b7-h3单克隆抗体的制备及其应用
CA2668800A1 (en) 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
US20100203035A1 (en) 2007-02-14 2010-08-12 Kwon Eugene D B7-h3 in cancer
CA2729593A1 (en) 2009-02-20 2010-08-26 John Wayne Cancer Institute B7-h3 as a biomarker for diagnosing the progression and early lymph node metastasis of cancer
US8802091B2 (en) * 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
PL2542256T3 (pl) * 2010-03-04 2020-01-31 Macrogenics, Inc. Przeciwciała reaktywne wobec b7-h3, ich immunologicznie czynne fragmenty i ich zastosowania
PT2703486T (pt) 2011-04-25 2018-05-18 Daiichi Sankyo Co Ltd Anticorpo anti-b7-h3
US9790282B2 (en) * 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
CA2947660C (en) 2014-05-29 2021-06-29 Spring Bioscience Corporation Anti-b7-h3 antibodies and diagnostic uses thereof
EA038798B1 (ru) 2014-08-27 2021-10-21 Мемориал Слоан-Кеттеринг Кэнсер Сентер Анти-b7h3 антитела и связанные соединения и применение
ES2875057T3 (es) 2014-09-17 2021-11-08 Us Health Anticuerpos anti-CD276 (B7H3)
AU2018243123A1 (en) 2017-03-31 2019-09-26 Changzhou Hansoh Pharmaceutical Co., Ltd. B7-H3 antibody, antigen-binding fragment thereof and medical use thereof

Also Published As

Publication number Publication date
EP3604337A1 (en) 2020-02-05
US20200031934A1 (en) 2020-01-30
EP3604337A4 (en) 2021-03-10
KR20190134614A (ko) 2019-12-04
CN109937212A (zh) 2019-06-25
RU2765306C2 (ru) 2022-01-28
TW201837056A (zh) 2018-10-16
CN109937212B (zh) 2022-06-21
US11680100B2 (en) 2023-06-20
WO2018177393A1 (zh) 2018-10-04
TWI796328B (zh) 2023-03-21
US20210101984A1 (en) 2021-04-08
CA3056474A1 (en) 2018-10-04
JP7158403B2 (ja) 2022-10-21
US10899837B2 (en) 2021-01-26
JP2020515251A (ja) 2020-05-28
AU2018243123A1 (en) 2019-09-26
RU2019132843A (ru) 2021-04-30
UA125593C2 (uk) 2022-04-27
BR112019019111A2 (pt) 2020-05-05
RU2019132843A3 (es) 2021-08-16

Similar Documents

Publication Publication Date Title
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
MX2019012233A (es) Anticuerpos anti-sirpa.
MX2018005720A (es) Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello.
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
WO2018115432A3 (en) COMPOUNDS FOR THE TREATMENT OF BOVINE OR PORCINE RESPIRATORY DISEASE
MX2020008122A (es) Anticuerpos anti-pd-1.
MX2020010119A (es) Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EP4252742A3 (en) Fluticasone furoate in the treatment of copd
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
MX2017005522A (es) Tratamiento novedoso de la cornea usando laminina.
MX2018007925A (es) Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
EP4043012A4 (en) MEDICINAL PRODUCTS FOR TREATING ARTERY DISEASES AND USE THEREOF
BR112019001130A2 (pt) uso de lactama e composição farmacêutica
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
WO2019055776A3 (en) Compositions and methods for treatment of diseases involving cxcl1 function
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.